Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC ...Middle East

New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this type of bladder cancer have limited choices beyond radical cystectomy, highlighting the...

Hence then, the article about johnson johnson s inlexzo gemcitabine intravesical system delivers 74 percent disease free survival at one year in bcg unresponsive high risk papillary only nmibc was published today ( Saturday 06/12/2025 - 12:27 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC )

Also on site :

• KLOS-FM host Uncle Joe Benson, one LA radio’s legendary voices, dies at 76
• Fitness Influencer Lee ‘Malibu’ Markham Admits He Falsely Claimed IED Injury
• OpenAI says Canada mass shooter evaded ban with second ChatGPT account